Conatus Pharmaceuticals Inc (NASDAQ:CNAT)’s stock price traded up 2.7% during mid-day trading on Tuesday . The company traded as high as $0.32 and last traded at $0.31, 157,455 shares traded hands during mid-day trading. A decline of 82% from the average session volume of 876,398 shares. The stock had previously closed at $0.30.
Separately, ValuEngine upgraded shares of Conatus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, March 3rd.
The firm’s 50-day moving average is $0.38 and its two-hundred day moving average is $0.37. The stock has a market cap of $9.89 million, a P/E ratio of -0.88 and a beta of 1.95.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings data on Wednesday, March 11th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). Conatus Pharmaceuticals had a negative return on equity of 50.66% and a negative net margin of 52.42%. The company had revenue of $0.53 million during the quarter.
Hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC bought a new position in Conatus Pharmaceuticals in the 4th quarter worth approximately $54,000. Geode Capital Management LLC raised its position in Conatus Pharmaceuticals by 10.6% in the 4th quarter. Geode Capital Management LLC now owns 264,326 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 25,243 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in Conatus Pharmaceuticals by 22.4% in the 4th quarter. Acadian Asset Management LLC now owns 1,003,211 shares of the biotechnology company’s stock worth $401,000 after purchasing an additional 183,863 shares during the last quarter. Hedge funds and other institutional investors own 13.78% of the company’s stock.
About Conatus Pharmaceuticals (NASDAQ:CNAT)
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Recommended Story: S&P/TSX Index
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.